Subacute cutaneous lupus erythematosus
MONDO:0015573Subacute cutaneous lupus erythematosus (SCLE) is a form of cutaneous lupus erythematosus (CLE) that can present either as a non-scarring, annular photo-distributed dermatosis or psoriasiform plaques. SCLE is associated with anti-Ro/SSA antibodies and can be drug-induced.
46 clinical trials for this condition and its sub-types, 11 tagged with Subacute cutaneous lupus erythematosus itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New pill aims to calm lupus skin flares in major trial
Disease control Recruiting nowThis study tests an experimental pill called enpatoran for people with lupus who have active skin rashes. About 202 participants will receive either the drug or a placebo for 24 weeks, while continuing their usual treatments. The goal is to see if enpatoran can significantly redu…
Phase 3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Lupus drug continuation trial offers hope for disease control
Disease control Recruiting nowThis study offers continued treatment with deucravacitinib for people with systemic lupus erythematosus (SLE) or related skin lupus who finished earlier trials. It aims to keep the disease under control by providing ongoing access to the medication. Only 35 participants are being…
Phase 4 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Old malaria drug may tame lupus skin flares
Disease control Recruiting nowThis study tests whether quinacrine, a medication originally used for malaria, can safely reduce skin rashes and sores in people with cutaneous lupus erythematosus (CLE). Participants receive either quinacrine or a placebo for 12 weeks, then all receive quinacrine for another 12 …
Phase 2 • Sponsor: Victoria Werth • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New pill could tame skin lupus flares
Disease control Recruiting nowThis study tests an oral medication called ICP-488 for people with cutaneous lupus erythematosus (CLE), a condition that causes painful skin rashes and lesions. About 105 adults aged 18–75 with moderate-to-severe CLE will receive either the drug or a placebo for 16 weeks. The mai…
Phase 2 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC